scholarly article | Q13442814 |
P50 | author | Nicola Fusco | Q57152324 |
P2093 | author name string | Stefano Ferrero | |
Alessandro Del Gobbo | |||
Gianluca Lopez | |||
Francesca Boggio | |||
P2860 | cites work | Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. | Q54382778 |
Polymeric immunoglobulin receptor. | Q55054602 | ||
COLORECTAL Polymeric Immunoglobulin Receptor Expression is Correlated with Hepatic Metastasis and Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis. | Q55059199 | ||
Differential expression of hMLH1 in sporadic human colorectal cancer tumors and distant metastases | Q57742390 | ||
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence | Q57781151 | ||
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? | Q61054490 | ||
Chromosome 20p11 gains are associated with liver-specific metastasis in patients with colorectal cancer | Q61481027 | ||
Reduced β-catenin and peroxisome proliferator–activated receptor–γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome | Q63430813 | ||
Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing | Q63753432 | ||
Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer | Q83014906 | ||
Prognostic value of nuclear β-catenin overexpression at invasive front in colorectal cancer for synchronous liver metastasis | Q83131187 | ||
Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer | Q86048936 | ||
Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution | Q87632805 | ||
Biomarkers in colorectal liver metastases | Q88175705 | ||
GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer | Q90369580 | ||
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance | Q24555727 | ||
Wnt/beta-catenin signaling: components, mechanisms, and diseases | Q24630938 | ||
Preoperative evaluation and oncologic principles of colon cancer surgery | Q24653695 | ||
Deficient mismatch repair: Read all about it (Review) | Q26796491 | ||
Role of surgery in colorectal cancer liver metastases | Q26830444 | ||
Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
Matrix metalloproteinases and cancer - roles in threat and therapy | Q27027389 | ||
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer | Q27824786 | ||
Global cancer statistics, 2012 | Q27860501 | ||
Integrins: versatility, modulation, and signaling in cell adhesion | Q27860844 | ||
HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists | Q28078111 | ||
The Ki-67 protein: from the known and the unknown | Q28143714 | ||
The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? | Q28295141 | ||
MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. | Q33612074 | ||
Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis | Q33648921 | ||
The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection. | Q33766412 | ||
Differential microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer | Q33829311 | ||
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. | Q33889158 | ||
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors | Q33929301 | ||
HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. | Q34324291 | ||
Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies | Q34801723 | ||
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases | Q35012020 | ||
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study | Q35577684 | ||
Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression | Q35672901 | ||
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. | Q36086837 | ||
The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis | Q36090214 | ||
The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. | Q51000683 | ||
MicroRNA-192-5p is a predictive biomarker of survival for Stage IIIB colon cancer patients. | Q52660672 | ||
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. | Q52845850 | ||
Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. | Q53491263 | ||
Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. | Q53686106 | ||
Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis. | Q54359070 | ||
MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. | Q54373557 | ||
CD133 expression is correlated with poor prognosis in colorectal cancer. | Q43605506 | ||
MACC1 is related to colorectal cancer initiation and early-stage invasive growth | Q43629517 | ||
Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. | Q43763382 | ||
SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases | Q43775981 | ||
Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer | Q43805357 | ||
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer | Q43807904 | ||
Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas | Q43972235 | ||
Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival | Q44052835 | ||
Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance | Q45331579 | ||
Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine | Q45788551 | ||
Prognostic value of CD133+ CD54+ CD44+ circulating tumor cells in colorectal cancer with liver metastasis | Q47099995 | ||
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). | Q47117539 | ||
Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis | Q47609839 | ||
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. | Q47620540 | ||
The histological growth pattern of colorectal cancer liver metastases has prognostic value | Q47942254 | ||
Prognostic significance of TBL1XR1 in predicting liver metastasis for early stage colorectal cancer | Q47945514 | ||
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers | Q49498310 | ||
In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers | Q50027073 | ||
miR-146a targets c-met and abolishes colorectal cancer liver metastasis. | Q50043556 | ||
Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres | Q36697911 | ||
Targeting NEK2 as a promising therapeutic approach for cancer treatment | Q36956969 | ||
Prognostic value of β1 integrin expression in colorectal liver metastases | Q37452274 | ||
Circulating and tissue biomarkers in early-stage non-small cell lung cancer | Q37629653 | ||
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions | Q37673704 | ||
Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity | Q37694789 | ||
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer | Q37709148 | ||
CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer | Q37718372 | ||
Role of the serrated pathway in colorectal cancer pathogenesis | Q37737403 | ||
MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. | Q37745844 | ||
Breast cancer intratumor genetic heterogeneity: causes and implications | Q38048815 | ||
Endoglin for targeted cancer treatment | Q38180309 | ||
Galectin-3 in cancer. | Q38188296 | ||
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer | Q38413100 | ||
CXCL12/SDF-1 and CXCR4. | Q38540516 | ||
EMX2 gene expression predicts liver metastasis and survival in colorectal cancer | Q38613759 | ||
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. | Q38699358 | ||
Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis. | Q38722886 | ||
RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy | Q38785379 | ||
Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). | Q38879266 | ||
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis | Q38952923 | ||
Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. | Q38954887 | ||
TGF-β: an emerging player in drug resistance | Q39105549 | ||
Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis | Q39119552 | ||
Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. | Q39182605 | ||
Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. | Q39339912 | ||
A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors | Q39570867 | ||
Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer | Q40258574 | ||
Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis | Q40501620 | ||
Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer | Q40776581 | ||
Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab | Q41175542 | ||
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer. | Q41247985 | ||
KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases | Q41548018 | ||
Correlations between TBL1XR1 and recurrence of colorectal cancer | Q41779003 | ||
Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer | Q42084826 | ||
Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis? | Q42316697 | ||
miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance | Q42921031 | ||
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy | Q43208381 | ||
Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents | Q43217749 | ||
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab | Q43538858 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunohistochemistry | Q899285 |
colorectal carcinoma | Q25493920 | ||
P577 | publication date | 2018-10-03 | |
P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
P1476 | title | Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma | |
P478 | volume | 19 |
Q93048439 | Special Issue on Basic and Translational Research in Colorectal Cancer | cites work | P2860 |
Search more.